Skip to content

Category: Clinical Updates

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial.

Weiss JM1, Csoszi T2, Maglakelidze M3, Hoyer RJ4, Beck JT5, Gomez MD6, Lowczak A7, Aljumaily R8, Lima CMR9, Boccia RV10, Hanna W11, Nikolinakos P12, Chiu VK13, Owonikoko TK14, Schuster SR15, Hussein MA16, Richards DA17, Sawrycki P18, Bulat I19, Hamm JT20, Hart LL21, Adler S22, Antal JM22, Lai AY22, Sorrentino JA22, Yang Z22, Malik RK22, Morris SR22, Roberts PJ22, Dragnev KH23; G1T28-02 Study Group.

 

https://www.ncbi.nlm.nih.gov/pubmed/31504118


Buparlisib plus fulvestrant in postmenopausal women

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O’Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T.

Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7.

PMID: 29223745


Ipatasertib plus paclitaxel versus placebo plus paclitaxel

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8.

PMID: 28800861